Condition Directory

Multiple Myeloma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Multiple Myeloma. Browse Multiple Myeloma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 2, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

965

Shown on this page

Current sort

How Multiple Myeloma studies are organized in the registry

Myeloma listings distinguish newly diagnosed from relapsed/refractory disease in their titles, and precursor conditions — smoldering myeloma and MGUS — are usually registered as separate condition terms. Cell-based and antibody platforms (CAR-T, bispecific antibodies) appear by name in many current titles.

Terms that often appear in related listings

relapsed refractory myeloma smoldering myeloma CAR-T bispecific

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 965 matching trials for Multiple Myeloma.

Live ClinicalTrials.gov results.

Active filters: "relapsed refractory myeloma" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Multiple Myeloma in Relapse
Interventions: Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Lymphoma, Myeloma, Leukemia
Interventions: Kappa CD28 T cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2035
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Iberdomide, Belantamab Mafodotin, Dexamethasone, Echocardiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection; Drug · Biological · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 43
States / cities: Ames, Iowa • Boone, Iowa • Fort Dodge, Iowa + 30 more

Conditions: Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions: Mirdametinib, Sirolimus; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma
Interventions: Ramantamig, Tocilizumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Goodyear, Arizona • Beverly Hills, California • Irvine, California + 2 more

Conditions: Advanced Hematologic Malignancies
Interventions: DSP-5336, [14C]-DSP-5336; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Houston, Texas

Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Interventions: Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, FDG-Positron Emission Tomography, Pomalidomide, Teclistamab; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 19
States / cities: Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 15 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 56
States / cities: Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more

Conditions: Multiple Myeloma
Interventions: ABBV-438; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Duarte, California • Irvine, California • Denver, Colorado + 4 more

Conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions: Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 5
States / cities: Atlanta, Georgia • New York, New York • Columbus, Ohio + 2 more

Conditions: Neoplasm Malignant
Interventions: SAR442257; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Duarte, California • Miami, Florida • Rochester, Minnesota

About this Multiple Myeloma clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Multiple Myeloma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Multiple Myeloma.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Multiple Myeloma clinical trials

How Multiple Myeloma studies are organized in the registry

Filter and sort this condition

Live official records

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

About this Multiple Myeloma clinical trials directory page